Results 21 to 30 of about 7,292 (203)

Facial hair enhancement with minoxidil—an off-label use

SAGE Open Medical Case Reports
Minoxidil was first introduced in the 1970s as an anti-hypertensive medication. Hypertrichosis and scalp hair regrowth were noted by users, and the topical formulation of minoxidil was later approved by the Food and Drug Administration for androgenic ...
Arveen Shokravi, Hanieh Zargham
doaj   +2 more sources

Advances in the Treatment of Androgenetic Alopecia: A Review of Mechanisms and the Clinical Efficacy of Combination Drug Therapy [PDF]

J Cosmet Dermatol
ABSTRACT Background Androgenetic alopecia (AGA) is the most prevalent type of hair loss, exerting a significant negative impact on patients' quality of life. The limited efficacy, potential adverse effects, and poor patient adherence of single‐agent therapies highlight substantial unmet needs in clinical management.
Lai Z, Zhou Y, Zhou R.
europepmc   +2 more sources

MONILETHRIX TREATED WITH MINOXIDIL [PDF]

, 2011
In literature many different therapies are proposed to treat Monilethrix, but a definitive therapy still doe not exist. We decided to treat four patients affected by Monilethrix, with topical minoxidil 2%, 1 ml night and day for 1 year.
A. Iorio, M. Carlesimo, CARLESIMO, Marta, A. Rossi, M.C. Fortuna, MARI, Elena, E. Palese, P. Greco, E. Mari, M. C. Fortuna, ROSSI, Alfredo, IORIO, ALESSANDRA, E. Scali   +12 more
core   +1 more source

Prolonged hypotension induced by ingesting a topical minoxidil solution: analysis of minoxidil and its metabolites

Acute Medicine & Surgery, 2016
Case A 47‐year‐old man ingested 60 mL of a topical solution (3,000 mg minoxidil) and presented with prolonged hypotension. Treatment with dopamine hydrochloride and noradrenaline provided blood pressure control.
Satoshi Kikuchi, Yuji Fujita, Makoto Onodera, Yasuhisa Fujino, Yoshihiro Inoue   +4 more
doaj   +1 more source

Characterization of Soluplus/ASC-DP Nanoparticles Encapsulated with Minoxidil for Skin Targeting

ChemEngineering, 2021
Soluplus (Sol) is an amphiphilic graft copolymer capable of forming self-assembled micelles and L-ascorbyl 2,6-dipalmitate (ASC-DP) aggregates spontaneously to form micelles.
Rina Takayama, Moe Ishizawa, Miyuki Yamada, Yutaka Inoue, Ikuo Kanamoto   +4 more
doaj   +1 more source

New Target for Minoxidil in the Treatment of Androgenetic Alopecia

Drug Design, Development and Therapy, 2023
Yuqing Shen,1 Yuqi Zhu,1 Li Zhang,1 Jiayi Sun,1 Bo Xie,2 Hongyan Zhang,2 Xiuzu Song2 1Department of Dermatology, Hangzhou Third People’s Hospital, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 2Department of Dermatology ...
Shen Y, Zhu Y, Zhang L, Sun J, Xie B, Zhang H, Song X   +6 more
doaj  

Effect of High-Dose Topical Minoxidil on Erythrocyte Quality in SKH1 Hairless Mice

Animals, 2020
SKH1 hairless mice are widely used in carcinogenesis and dermatology research due to their bare skin, as exposure to different agents is facilitated. Minoxidil is a cosmetic drug that is recognized as a mitogenic agent, and mitogens are suggested to have
Eduardo Naranjo-Vázquez, María Guadalupe Sánchez-Parada, Belinda Claudia Gómez-Meda, Ana Lourdes Zamora-Perez, Martha Patricia Gallegos-Arreola, Ana Elizabeth González-Santiago, Guillermo Moisés Zúñiga-González   +6 more
doaj   +1 more source

A Theoretical Model for the Treatment of Androgenetic Alopecia Using the STEAP3 Protein, and the Genetic Challenges of Treating AGA [PDF]

Health Sci Rep
ABSTRACT Background and Aims Androgenetic alopecia (AGA) is a prevalent condition. The treatment methods currently available for this condition have limited potential (minoxidil) and side effects with long‐term therapy that affect the physiology of the male population (5α‐reductase inhibitors).
Młodzianowski I, Grochocka M, Tadrowski T, Hałas‐Wiśniewska M, Izdebska M.   +4 more
europepmc   +2 more sources

Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride

Indian Dermatology Online Journal, 2015
Background: Finasteride acts by reducing dihydrotestosterone levels, thereby inhibiting miniaturization of hair follicles in patients with androgenetic alopecia (AGA).
B S Chandrashekar, T Nandhini, Vani Vasanth, Rashmi Sriram, Shreya Navale   +4 more
doaj   +1 more source

Comparison between “5% minoxidil plus 2% flutamide” solution vs. “5% minoxidil” solution in the treatment of androgenetic alopecia

, 2022
Background Androgenetic alopecia is defined as a patterned hair loss resulting from the effect of androgen on hair follicles and characterized by non-scarring, progressive miniaturization of the hair follicles.
Mina Saber, Iraji, F., Maedeh Sadat Hoseyni, Siadat, A. H., Jelvan, M., Amir Hossein Siadat, Minoo Jelvan, Hoseyni, M. S., Faghihi, G., Fariba Iraji, Gita Faghihi, Saber, M.   +11 more
core   +1 more source